Ryan Bitton, PharmD, MBA, and Frank J. Palella, MD, discuss facts about the implementation of USPSTF guidelines for HIV PrEP therapy. Ryan Haumschild, PharmD, MS, MBA: Thank you. It’s such a complex ...
In their recent response to my earlier article, Amy Killelea and Jeremiah Johnson take a position that overlooks patient access concerns and undermines innovation toward newer and better forms of PrEP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results